MIY as a free ligand exists in 14 entries. Examples include: 5ENT 4U8Y 2XPV

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

FormulaC23 H27 N3 O7
Molecular Weight457.48
Isomeric SMILESCN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)N(C)C

Chemical Details

Formal Charge0
Atom Count60
Chiral Atom Count4
Chiral AtomsC18, C4, C5, C7
Bond Count63
Aromatic Bond Count6
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB01017 Different stereochemistry
  • approved
  • investigational
DescriptionA tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. [PubChem]
  • (4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
  • 7-Dimethylamino-6-demethyl-6-deoxytetracycline
  • Minociclina
  • Minociclinum
  • Minocyclin
SaltsMinocycline hydrochloride
Brand Names
  • Apo-minocycline Cap 100mg
  • Apo-minocycline Cap 50mg
  • Arestin
  • Arestin Microspheres
  • Dom-minocycline Caps
Affected OrganismEnteric bacteria and other eubacteria
IndicationFor the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by <i>Streptococcus pneumoniae</i> and for the treatment of asymptomatic carriers of <i>Neisseria meningitidis</i>.
PharmacologyMinocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against <i>Neisseria meningitidis</i>, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.
Mechanism of actionMinocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Tetracyclines like minocycline bind to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.
Route of administration
  • Intravenous
  • Oral
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antibacterials for Systemic Use
  • Antiinfectives for Systemic Use
  • Chemical Actions and Uses
  • A01AB23
  • J01AA08
CAS number10118-90-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682